董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Simon D. Campion | 男 | Director,President and Chief Executive Officer | 52 | 755.24万美元 | 未持股 | 2024-01-01 |
| Janet S. Vergis | 女 | Independent Director | 59 | 31.50万美元 | 0.99 | 2024-01-01 |
| Jonathan J. Mazelsky | 男 | Independent Director | 63 | 未披露 | 未持股 | 2024-01-01 |
| Dorothea Wenzel | 女 | Independent Director | 55 | 31.06万美元 | 未持股 | 2024-01-01 |
| Brian Gladden | 男 | Independent Director | -- | 未披露 | 未持股 | 2024-01-01 |
| Eric K. Brandt | 男 | Non-Executive Chairman | 61 | 47.50万美元 | 9.60 | 2024-01-01 |
| Clyde R. Hosein | 男 | Independent Director | 64 | 30.00万美元 | 0.63 | 2024-01-01 |
| Leslie F. Varon | 女 | Independent Director | 67 | 32.50万美元 | 2.38 | 2024-01-01 |
| Willie A. Deese | 男 | Independent Director | 68 | 32.00万美元 | 6.41 | 2024-01-01 |
| Betsy D. Holden | 女 | Independent Director | 68 | 31.50万美元 | 2.77 | 2024-01-01 |
| Gregory T. Lucier | 男 | Independent Director | 59 | 30.00万美元 | 3.63 | 2024-01-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Simon D. Campion | 男 | Director,President and Chief Executive Officer | 52 | 755.24万美元 | 未持股 | 2024-01-01 |
| Lisa M. Yankie | 女 | Senior Vice President, Chief Human Resources Officer and Communications | 55 | 116.94万美元 | 未持股 | 2024-01-01 |
| Erania Brackett | 女 | Senior Vice President, Chief Marketing Officer | 49 | 未披露 | 未持股 | 2024-01-01 |
| Andreas G. Frank | 男 | Executive Vice President | 47 | 724.71万美元 | 未持股 | 2024-01-01 |
| Robert A. Johnson | 男 | Chief Supply Chain Officer | 55 | 未披露 | 未持股 | 2024-01-01 |
| Richard C. Rosenzweig | 男 | Senior Vice President, Corporate Development, General Counsel and Secretary | 57 | 未披露 | 未持股 | 2024-01-01 |
| Richard M. Wagner | 男 | Chief Accounting Officer | 56 | 未披露 | 未持股 | 2024-01-01 |
| Glenn G. Coleman | 男 | Executive Vice President and Chief Financial Officer | 56 | 422.08万美元 | 未持股 | 2024-01-01 |
董事简历
中英对照 | 中文 | 英文- Simon D. Campion
-
Simon D. Campion自2022年9月12日起担任Dentsply Sirona Inc.总裁兼首席执行官，并担任Dentsply Sirona Inc.董事会成员。在加入Dentsply Sirona之前，Campion先生曾担任Becton，Dickinson and Company（“BD”）的执行副总裁兼医疗部门总裁，该职位于2022年7月开始担任。在此之前，Campion先生自2018年9月起担任BD干预部门的执行副总裁兼总裁，在此之前，他是BD手术业务部门的总裁，在那里他将传统的C.R.Bard，Inc.（“Bard”）和BD产品平台集成到一个集成手术产品中。Campion先生于2008年加入Bard，在美国和国际上的许多Bard公司担任领导职务。在加入Bard之前，他曾在Cook Medical和Boston Scientific担任营销和研发职务。Campion先生拥有University of Limerick in Ireland机械工程博士学位和The Open University in the United Kingdom工商管理硕士学位。
Simon D. Campion,has served as Dentsply Sirona Inc. President and Chief Executive Officer and as a member of the Company's Board of Directors since September 12, 2022. Prior to joining Dentsply Sirona, Mr. Campion served as the Executive Vice President and President of the Medical Segment of Becton, Dickinson and Company ("BD"), a position held beginning in July 2022. Prior to that, Mr. Campion served as the Executive Vice President and President of the Interventional segment for BD since September 2018 and, prior to that, he was president of the BD Surgery business unit, where he integrated legacy C. R. Bard, Inc. ("Bard") and BD product platforms into an integrated surgery offering. Mr. Campion joined Bard in 2008 and held leadership roles in numerous Bard businesses in the U.S. and Internationally. Prior to Bard, he held marketing and R&D roles at Cook Medical and Boston Scientific. Mr. Campion holds a Ph.D. in Mechanical Engineering from the University of Limerick in Ireland and a Master of Business Administration from The Open University in the United Kingdom. - Simon D. Campion自2022年9月12日起担任Dentsply Sirona Inc.总裁兼首席执行官，并担任Dentsply Sirona Inc.董事会成员。在加入Dentsply Sirona之前，Campion先生曾担任Becton，Dickinson and Company（“BD”）的执行副总裁兼医疗部门总裁，该职位于2022年7月开始担任。在此之前，Campion先生自2018年9月起担任BD干预部门的执行副总裁兼总裁，在此之前，他是BD手术业务部门的总裁，在那里他将传统的C.R.Bard，Inc.（“Bard”）和BD产品平台集成到一个集成手术产品中。Campion先生于2008年加入Bard，在美国和国际上的许多Bard公司担任领导职务。在加入Bard之前，他曾在Cook Medical和Boston Scientific担任营销和研发职务。Campion先生拥有University of Limerick in Ireland机械工程博士学位和The Open University in the United Kingdom工商管理硕士学位。
- Simon D. Campion,has served as Dentsply Sirona Inc. President and Chief Executive Officer and as a member of the Company's Board of Directors since September 12, 2022. Prior to joining Dentsply Sirona, Mr. Campion served as the Executive Vice President and President of the Medical Segment of Becton, Dickinson and Company ("BD"), a position held beginning in July 2022. Prior to that, Mr. Campion served as the Executive Vice President and President of the Interventional segment for BD since September 2018 and, prior to that, he was president of the BD Surgery business unit, where he integrated legacy C. R. Bard, Inc. ("Bard") and BD product platforms into an integrated surgery offering. Mr. Campion joined Bard in 2008 and held leadership roles in numerous Bard businesses in the U.S. and Internationally. Prior to Bard, he held marketing and R&D roles at Cook Medical and Boston Scientific. Mr. Campion holds a Ph.D. in Mechanical Engineering from the University of Limerick in Ireland and a Master of Business Administration from The Open University in the United Kingdom.
- Janet S. Vergis
-
Janet S. Vergis 在医疗保健行业有超过30年的经验，最近担任私人股本公司的执行顾问。担任顾问之前，她曾担任OraPharma,lnc的首席执行官。OraPharma,lnc 公司是一家专注于口腔健康的私营专业制药公司。在担任该职位期间，她带领公司扭亏为盈，并在随后成功出售。在OraPharma任职之前，她曾管理Johnson & Johnson NYSE： JNJ的60亿美元投资组合，担任Janssen Pharmaceuticals、McNeil Pediatrics和Ortho-McNeil Neurologies的总裁。在她的职业生涯中，她曾为多个Johnson & Johnson公司做出贡献，担任公司管理委员会成员超过10年，并在研发、新产品开发、销售和市场营销方面担任越来越重要的职位。她担任Church and Dwight Co.， Inc. （NYSE： CHD）和MedDay Pharmaceuticals的董事会成员。她也是生物技术咨询委员会主席，埃伯利科学学院院长咨询顾问委员会成员，宾夕法尼亚州立大学公司和基金会关系咨询委员会副主席。她持有The Pennsylvania State University的生物学学士学位和生理学硕士学位。
Janet S. Vergis,served as an Executive Advisor for private equity firms from January 2013 to December 2019, where she identified and evaluated healthcare investment opportunities. From January 2011 to August 2012, she was the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company dedicated to oral health, where she led that company's successful turnaround and its subsequent sale. From 2004 to 2009, Ms. Vergis served as President of Janssen Pharmaceuticals, McNeil Pediatrics and Ortho-McNeil Neurologics. From 1988 to 2004, she served in various positions of increasing responsibility in executive leadership, research and development, new product development, sales, and marketing with Johnson & Johnson and its subsidiaries.Ms. Vergis is currently a member of the board of directors of Teva Pharmaceutical Industries, a global leader in generics and biopharmaceuticals, Dentsply Sirona, the world's largest manufacturer of professional dental solutions and SGS, a leading testing, inspection and certification company. She was also a member of the board of directors of Amneal Pharmaceuticals, Inc. and MedDay Pharmaceuticals from 2015 to 2019 and 2016 to 2021, respectively. - Janet S. Vergis 在医疗保健行业有超过30年的经验，最近担任私人股本公司的执行顾问。担任顾问之前，她曾担任OraPharma,lnc的首席执行官。OraPharma,lnc 公司是一家专注于口腔健康的私营专业制药公司。在担任该职位期间，她带领公司扭亏为盈，并在随后成功出售。在OraPharma任职之前，她曾管理Johnson & Johnson NYSE： JNJ的60亿美元投资组合，担任Janssen Pharmaceuticals、McNeil Pediatrics和Ortho-McNeil Neurologies的总裁。在她的职业生涯中，她曾为多个Johnson & Johnson公司做出贡献，担任公司管理委员会成员超过10年，并在研发、新产品开发、销售和市场营销方面担任越来越重要的职位。她担任Church and Dwight Co.， Inc. （NYSE： CHD）和MedDay Pharmaceuticals的董事会成员。她也是生物技术咨询委员会主席，埃伯利科学学院院长咨询顾问委员会成员，宾夕法尼亚州立大学公司和基金会关系咨询委员会副主席。她持有The Pennsylvania State University的生物学学士学位和生理学硕士学位。
- Janet S. Vergis,served as an Executive Advisor for private equity firms from January 2013 to December 2019, where she identified and evaluated healthcare investment opportunities. From January 2011 to August 2012, she was the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company dedicated to oral health, where she led that company's successful turnaround and its subsequent sale. From 2004 to 2009, Ms. Vergis served as President of Janssen Pharmaceuticals, McNeil Pediatrics and Ortho-McNeil Neurologics. From 1988 to 2004, she served in various positions of increasing responsibility in executive leadership, research and development, new product development, sales, and marketing with Johnson & Johnson and its subsidiaries.Ms. Vergis is currently a member of the board of directors of Teva Pharmaceutical Industries, a global leader in generics and biopharmaceuticals, Dentsply Sirona, the world's largest manufacturer of professional dental solutions and SGS, a leading testing, inspection and certification company. She was also a member of the board of directors of Amneal Pharmaceuticals, Inc. and MedDay Pharmaceuticals from 2015 to 2019 and 2016 to 2021, respectively.
- Jonathan J. Mazelsky
-
Jonathan J. Mazelsky，自2019年10月起担任IDEXX Laboratories, Inc.的总裁兼首席执行官。在此之前，mazelsky先生于2019年6月至2019年10月担任IDEXX的临时总裁兼首席执行官，并于2012年8月至2019年6月担任执行副总裁，负责IDEXX北美Companion Animal Group 商业组织和创新组合的关键要素，包括IDEXX VetLab内部诊断、诊断成像、兽医软件和服务、快速检测和远程医疗业务线。加入IDEXX之前，他曾担任Philips Healthcare （Royal Philips Electronics（现命名为Royal Philips）的子公司）的计算机断层扫描、核医学和放射治疗规划高级副总裁兼总经理（从2010年到2012年）。在此之前，从2001年开始，他在Philips任职期间担任了一系列其他领导职务，并承担了越来越多的责任。加入Philips之前，他曾任职Agilent Technologies，从2000年到2002年担任执行主管，领导将Agilent的医疗保健集团整合到Philips。1997年至2000年，他还担任Agilent Technologies的医疗耗材业务部总经理。从1988年到1996年，他在Hewlett Packard担任财务、营销和商业规划方面的多个职位。他持有罗切斯特大学（University of Rochester）数学学士学位和芝加哥大学（University of Chicago）工商管理硕士学位。
Jonathan J. Mazelsky,has served as President and CEO of IDEXX since October 2019. Prior to that, Mr. Mazelsky served as Idexx Laboratories, Inc. Interim President and CEO from June 2019 to October 2019, and he was an Executive Vice President responsible for Idexx Laboratories, Inc. North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including Idexx Laboratories, Inc. IDEXX VetLab in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business, from August 2012 to June 2019. Before joining IDEXX, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now named Royal Philips). Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent's Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit at Agilent Technologies from 1997 to 2000. From 1988 to 1996, Mr. Mazelsky held a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds an undergraduate degree in Mathematics from the University of Rochester and an MBA from the University of Chicago. - Jonathan J. Mazelsky，自2019年10月起担任IDEXX Laboratories, Inc.的总裁兼首席执行官。在此之前，mazelsky先生于2019年6月至2019年10月担任IDEXX的临时总裁兼首席执行官，并于2012年8月至2019年6月担任执行副总裁，负责IDEXX北美Companion Animal Group 商业组织和创新组合的关键要素，包括IDEXX VetLab内部诊断、诊断成像、兽医软件和服务、快速检测和远程医疗业务线。加入IDEXX之前，他曾担任Philips Healthcare （Royal Philips Electronics（现命名为Royal Philips）的子公司）的计算机断层扫描、核医学和放射治疗规划高级副总裁兼总经理（从2010年到2012年）。在此之前，从2001年开始，他在Philips任职期间担任了一系列其他领导职务，并承担了越来越多的责任。加入Philips之前，他曾任职Agilent Technologies，从2000年到2002年担任执行主管，领导将Agilent的医疗保健集团整合到Philips。1997年至2000年，他还担任Agilent Technologies的医疗耗材业务部总经理。从1988年到1996年，他在Hewlett Packard担任财务、营销和商业规划方面的多个职位。他持有罗切斯特大学（University of Rochester）数学学士学位和芝加哥大学（University of Chicago）工商管理硕士学位。
- Jonathan J. Mazelsky,has served as President and CEO of IDEXX since October 2019. Prior to that, Mr. Mazelsky served as Idexx Laboratories, Inc. Interim President and CEO from June 2019 to October 2019, and he was an Executive Vice President responsible for Idexx Laboratories, Inc. North American Companion Animal Group Commercial Organization and key elements of the innovation portfolio, including Idexx Laboratories, Inc. IDEXX VetLab in-house diagnostics, Diagnostic Imaging, Veterinary Software and Services, Rapid Assay and Telemedicine lines of business, from August 2012 to June 2019. Before joining IDEXX, Mr. Mazelsky was a Senior Vice President and General Manager from 2010 to 2012 of Computed Tomography, Nuclear Medicine and Radiation Therapy Planning at Philips Healthcare, a subsidiary of Royal Philips Electronics (now named Royal Philips). Previously he held a series of other leadership roles with increasing responsibilities during his tenure at Philips beginning in 2001. Prior to joining Philips, Mr. Mazelsky was at Agilent Technologies, where he was an Executive in Charge from 2000 to 2002, leading the integration of Agilent's Healthcare Group into Philips. He also served as a General Manager of the Medical Consumables Business Unit at Agilent Technologies from 1997 to 2000. From 1988 to 1996, Mr. Mazelsky held a number of roles at Hewlett Packard in finance, marketing and business planning. Mr. Mazelsky holds an undergraduate degree in Mathematics from the University of Rochester and an MBA from the University of Chicago.
- Dorothea Wenzel
-
Dorothea Wenzel 于 2004 年 6 月至 2021 年 8 月在德国达姆施塔特的默克公司任职，最近一次是自 2019 年以来担任执行副总裁兼表面解决方案业务部负责人。此前，她在 2018 年担任高性能材料部门的首席财务官，从 2014 年到 2018 年，Wenzel 博士领导了医疗保健部门的生育特许经营权，在此之前，从 2006 年到 2013 年，她担任了医疗保健部门的首席财务官。在加入德国达姆施塔特默克公司之前，Wenzel 博士曾在 AXA Krankenversicherung AG 和 Medvantis Holding AG 的医疗保健行业担任过多个财务和商业职位，并在 McKinsey & Comp 担任了数年的顾问和项目经理。 Wenzel 博士还是德国联邦卫生部社会保障系统融资可持续性委员会的工作人员。 Wenzel 博士在 Fresenius Medical Care AG & Co. KGaA 董事会担任首席独立董事，并在 H. Lundbeck S/A 董事会担任审计委员会主席。 Wenzel 博士拥有达姆施塔特工业大学的卫生经济学博士学位和商业与计算机科学文凭。
Dorothea Wenzel served for Merck KGaA, Darmstadt Germany, from June 2004 to August 2021 most recently since 2019 as Executive Vice President and Head of the Surface Solutions Business Unit. Previously, in 2018 she was CFO of the Performance Materials Division and from 2014 to 2018 Dr. Wenzel headed the Fertility Franchise in the Healthcare division and, prior to that, from 2006 to 2013 she was the CFO of the Healthcare Division. Prior to joining Merck KGaA, Darmstadt Germany, Dr. Wenzel held a number of finance and business positions in the health care industry at AXA Krankenversicherung AG and Medvantis Holding AG and worked for several years as consultant and engagement manager at McKinsey & Comp. Dr. Wenzel was also a Member of the Staff of the Committee for the Sustainability of the Financing of the Social Security Systems of the Federal Ministry of Health Germany. Dr. Wenzel serves on the Board of Fresenius Medical Care AG & Co. KGaA as Lead Independent Director and on the Board of H. Lundbeck S/A as Chair of the Audit Committee. Dr. Wenzel holds a doctorate in Health Economics and a diploma in business & computer sciences from the Technical University of Darmstadt. - Dorothea Wenzel 于 2004 年 6 月至 2021 年 8 月在德国达姆施塔特的默克公司任职，最近一次是自 2019 年以来担任执行副总裁兼表面解决方案业务部负责人。此前，她在 2018 年担任高性能材料部门的首席财务官，从 2014 年到 2018 年，Wenzel 博士领导了医疗保健部门的生育特许经营权，在此之前，从 2006 年到 2013 年，她担任了医疗保健部门的首席财务官。在加入德国达姆施塔特默克公司之前，Wenzel 博士曾在 AXA Krankenversicherung AG 和 Medvantis Holding AG 的医疗保健行业担任过多个财务和商业职位，并在 McKinsey & Comp 担任了数年的顾问和项目经理。 Wenzel 博士还是德国联邦卫生部社会保障系统融资可持续性委员会的工作人员。 Wenzel 博士在 Fresenius Medical Care AG & Co. KGaA 董事会担任首席独立董事，并在 H. Lundbeck S/A 董事会担任审计委员会主席。 Wenzel 博士拥有达姆施塔特工业大学的卫生经济学博士学位和商业与计算机科学文凭。
- Dorothea Wenzel served for Merck KGaA, Darmstadt Germany, from June 2004 to August 2021 most recently since 2019 as Executive Vice President and Head of the Surface Solutions Business Unit. Previously, in 2018 she was CFO of the Performance Materials Division and from 2014 to 2018 Dr. Wenzel headed the Fertility Franchise in the Healthcare division and, prior to that, from 2006 to 2013 she was the CFO of the Healthcare Division. Prior to joining Merck KGaA, Darmstadt Germany, Dr. Wenzel held a number of finance and business positions in the health care industry at AXA Krankenversicherung AG and Medvantis Holding AG and worked for several years as consultant and engagement manager at McKinsey & Comp. Dr. Wenzel was also a Member of the Staff of the Committee for the Sustainability of the Financing of the Social Security Systems of the Federal Ministry of Health Germany. Dr. Wenzel serves on the Board of Fresenius Medical Care AG & Co. KGaA as Lead Independent Director and on the Board of H. Lundbeck S/A as Chair of the Audit Committee. Dr. Wenzel holds a doctorate in Health Economics and a diploma in business & computer sciences from the Technical University of Darmstadt.
- Brian Gladden
-
Brian Gladden，现任Zelis Healthcare Inc（“Zelis”）的首席行政和首席财务官。在加入Zelis之前，他是Bain Capital北美私募股权团队的运营合伙人。加入Bain Capital之前，他曾担任上市公司Mondelēz International, Inc.和Dell, Inc.的首席财务官。他的职业生涯始于通用电气公司（General Electric Company），担任了近20年的各种高级财务和管理职位，包括GE Plastics的总裁兼首席执行官，以及塑料和医疗保健业务的部门首席财务官。他目前担任美国重症肌无力基金会主席，米勒斯维尔大学隆巴多商学院和德克萨斯大学奥斯汀分校麦库姆斯商学院咨询委员会成员。他拥有米勒斯维尔大学（Millersville University）工商管理和金融学士学位。
Brian Gladden,is currently the Chief Administrative and Chief Financial Officer of Zelis Healthcare Inc ("Zelis"). Before Zelis, Mr. Gladden was an Operating Partner with Bain Capital's North American Private Equity team. Prior to Bain Capital, Mr. Gladden was Chief Financial Officer at public companies Mondelēz International, Inc. and Dell, Inc. He began his career at General Electric Company, serving for nearly two decades in various senior finance and management positions, including as President and Chief Executive Officer of GE Plastics and divisional Chief Financial Officer roles in the Plastics and Healthcare businesses. Mr. Gladden currently serves as the Chair of the Myasthenia Gravis Foundation of America and as a member of the Advisory Councils for both the Lombardo College of Business at Millersville University and the McCombs School of Business at the University of Texas – Austin. He has a Bachelor of Science in Business Administration and Finance from Millersville University. - Brian Gladden，现任Zelis Healthcare Inc（“Zelis”）的首席行政和首席财务官。在加入Zelis之前，他是Bain Capital北美私募股权团队的运营合伙人。加入Bain Capital之前，他曾担任上市公司Mondelēz International, Inc.和Dell, Inc.的首席财务官。他的职业生涯始于通用电气公司（General Electric Company），担任了近20年的各种高级财务和管理职位，包括GE Plastics的总裁兼首席执行官，以及塑料和医疗保健业务的部门首席财务官。他目前担任美国重症肌无力基金会主席，米勒斯维尔大学隆巴多商学院和德克萨斯大学奥斯汀分校麦库姆斯商学院咨询委员会成员。他拥有米勒斯维尔大学（Millersville University）工商管理和金融学士学位。
- Brian Gladden,is currently the Chief Administrative and Chief Financial Officer of Zelis Healthcare Inc ("Zelis"). Before Zelis, Mr. Gladden was an Operating Partner with Bain Capital's North American Private Equity team. Prior to Bain Capital, Mr. Gladden was Chief Financial Officer at public companies Mondelēz International, Inc. and Dell, Inc. He began his career at General Electric Company, serving for nearly two decades in various senior finance and management positions, including as President and Chief Executive Officer of GE Plastics and divisional Chief Financial Officer roles in the Plastics and Healthcare businesses. Mr. Gladden currently serves as the Chair of the Myasthenia Gravis Foundation of America and as a member of the Advisory Councils for both the Lombardo College of Business at Millersville University and the McCombs School of Business at the University of Texas – Austin. He has a Bachelor of Science in Business Administration and Finance from Millersville University.
- Eric K. Brandt
-
Eric K. Brandt，在2007年3月加入博通公司担任高级副总裁兼财务总监。2010年2月，他成为执行副总裁兼财务总监。他还在部分博通附属公司担任主管及高级职员。从2005年9月至2007年3月，布兰特先生担任总裁AVANIR制药公司的总裁兼CEO。在加入AVANIR之前，勃兰特先生是艾尔建公司财政和技术运营部的执行副总裁兼财务总监， 这是一家全球性专业制药公司；在1999年加入Allergan制药公司后他还担任了各种其他高级职位。之前，勃兰特先生在波士顿咨询集团任职十年，这是一家私人持有的全球商业咨询公司，最近担任该公司副总裁兼合伙人；并且是该公司的卫生保健实践的高级成员。此外，在波士顿咨询集团任职时，他负责北美业务实践和为计算机和电信客户提供咨询。他是丹普莱国际公司的主管，这是一家公开上市的牙科产品公司；兼Lam研究公司的主管，这是一家公开上市的晶圆制造设备公司。勃兰特先生拥有麻省理工学院的化学工程学士学位和哈佛商学院的工商管理硕士学位。
Eric K. Brandt,is the former Executive Vice President and Chief Financial Officer of Broadcom Corporation, a global supplier of semiconductor devices, a position he held from March 2007 until its merger with Avago Technologies Limited in February 2016. From September 2005 to March 2007, Mr. Brandt served as President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a pharmaceutical company. Prior to Avanir Pharmaceuticals, Mr. Brandt was Executive Vice President-Finance and Technical Operations and Chief Financial Officer of Allergan Inc., a global specialty pharmaceutical company, where he also held a number of other senior positions following his arrival there in May 1999.Mr. Brandt has served as a member of the board of directors of: Gen Digital Inc. (formerly NortonLifeLock, Inc.), a consumer cyber security provider, since February 2020, where he is the chair of the audit committee; The Macerich Company, a real estate investment trust focused on regional malls, since June 2018, where he is the chair of the capital allocation committee and a member of the compensation committee; Altaba Inc. (formerly Yahoo! Inc.), a private company that remained, and was subsequently renamed, following the completion of Yahoo!'s sale of its operating businesses in June 2017 (and which is in the process of a stockholder approved plan of dissolution and liquidation), since its inception, where he is the lead independent director and chair of the audit committee, and has served as chairman of the board, chair of the nominating and governance committee, and a member of the compensation committee; and Dentsply Sirona Inc. (formerly Dentsply International, Inc.), a manufacturer and distributor of dental product solutions, since 2004, where he is the non-executive chairman of the board and a member of the corporate governance and nominating committee, and has served as chair of the executive committee and a member of the human resources committee and the audit and finance committee.He previously served on the board of directors of: MC10, Inc., a privately-held medical device Internet of Things (IoT) company, from March 2016 until February 2018, where he was chair of the compensation committee and governance committee; Yahoo! Inc., a digital information discovery company, from March 2016 to June 2017, where he was chairman of the board and chair of the audit and finance committee; Vertex Pharmaceuticals, Inc., a pharmaceutical company, from 2002 to 2009, where he was chair of the audit committee, and a member of the nominating and governance committee; and Avanir Pharmaceuticals from 2005 to 2007.Mr. Brandt earned an M.B.A. degree from the Harvard Graduate School of Business and a B.S. degree in chemical engineering from the Massachusetts Institute of Technology. - Eric K. Brandt，在2007年3月加入博通公司担任高级副总裁兼财务总监。2010年2月，他成为执行副总裁兼财务总监。他还在部分博通附属公司担任主管及高级职员。从2005年9月至2007年3月，布兰特先生担任总裁AVANIR制药公司的总裁兼CEO。在加入AVANIR之前，勃兰特先生是艾尔建公司财政和技术运营部的执行副总裁兼财务总监， 这是一家全球性专业制药公司；在1999年加入Allergan制药公司后他还担任了各种其他高级职位。之前，勃兰特先生在波士顿咨询集团任职十年，这是一家私人持有的全球商业咨询公司，最近担任该公司副总裁兼合伙人；并且是该公司的卫生保健实践的高级成员。此外，在波士顿咨询集团任职时，他负责北美业务实践和为计算机和电信客户提供咨询。他是丹普莱国际公司的主管，这是一家公开上市的牙科产品公司；兼Lam研究公司的主管，这是一家公开上市的晶圆制造设备公司。勃兰特先生拥有麻省理工学院的化学工程学士学位和哈佛商学院的工商管理硕士学位。
- Eric K. Brandt,is the former Executive Vice President and Chief Financial Officer of Broadcom Corporation, a global supplier of semiconductor devices, a position he held from March 2007 until its merger with Avago Technologies Limited in February 2016. From September 2005 to March 2007, Mr. Brandt served as President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a pharmaceutical company. Prior to Avanir Pharmaceuticals, Mr. Brandt was Executive Vice President-Finance and Technical Operations and Chief Financial Officer of Allergan Inc., a global specialty pharmaceutical company, where he also held a number of other senior positions following his arrival there in May 1999.Mr. Brandt has served as a member of the board of directors of: Gen Digital Inc. (formerly NortonLifeLock, Inc.), a consumer cyber security provider, since February 2020, where he is the chair of the audit committee; The Macerich Company, a real estate investment trust focused on regional malls, since June 2018, where he is the chair of the capital allocation committee and a member of the compensation committee; Altaba Inc. (formerly Yahoo! Inc.), a private company that remained, and was subsequently renamed, following the completion of Yahoo!'s sale of its operating businesses in June 2017 (and which is in the process of a stockholder approved plan of dissolution and liquidation), since its inception, where he is the lead independent director and chair of the audit committee, and has served as chairman of the board, chair of the nominating and governance committee, and a member of the compensation committee; and Dentsply Sirona Inc. (formerly Dentsply International, Inc.), a manufacturer and distributor of dental product solutions, since 2004, where he is the non-executive chairman of the board and a member of the corporate governance and nominating committee, and has served as chair of the executive committee and a member of the human resources committee and the audit and finance committee.He previously served on the board of directors of: MC10, Inc., a privately-held medical device Internet of Things (IoT) company, from March 2016 until February 2018, where he was chair of the compensation committee and governance committee; Yahoo! Inc., a digital information discovery company, from March 2016 to June 2017, where he was chairman of the board and chair of the audit and finance committee; Vertex Pharmaceuticals, Inc., a pharmaceutical company, from 2002 to 2009, where he was chair of the audit committee, and a member of the nominating and governance committee; and Avanir Pharmaceuticals from 2005 to 2007.Mr. Brandt earned an M.B.A. degree from the Harvard Graduate School of Business and a B.S. degree in chemical engineering from the Massachusetts Institute of Technology.
- Clyde R. Hosein
-
Clyde R. Hosein，2005年12月起，他是董事会成员；2013年8月起，他担任RingCentral（软件服务云为基础的商业通信解决方案供应商）行政副总裁兼首席财务官；2008年6月至2012年10月，他在Marvell Technology Group Ltd（高性能模拟，混合信号，数字信号处理和嵌入式微处理器集成电路的公开交易的半导体供应商）担任首席财务官；2008年10月至2010年3月，他还是Marvell Technology Group Ltd候补首席运营官兼秘书；2003年至2008年，他是Integrated Device Technology（重要混合信号半导体解决方案供应商）副总裁兼首席财务官；2001年至2003年，他是Advanced Interconnect Technologies（半导体封装和测试公司）财务部、行政部高级副总裁兼首席财务官。他还在Candescent Technologies（开发的平板显示技术开发商）担任过多个高级财务职位。在他的职业生涯早期，他在IBM Corporation的财务和工程方面工作14年。Hosein先生拥有纽约大学斯特恩商学院工商管理硕士学位和纽约理工大学工业工程学士学位。
Clyde R. Hosein has served as Chief Financial Officer of AliveCor Inc., a medical device and AI company producing ECG hardware and software for consumer mobile devices, since March 2021. Prior to AliveCor, Mr. Hosein served as Chief Financial Officer of Automation Anywhere, Inc., an enterprise software provider of robotic process automation, from December 2017 to March 2021. From August 2013 to May 2017 he served as Executive Vice President and Chief Financial Officer of RingCentral, Inc., a publicly traded provider of software-as-a-service cloud-based business communications solutions. Prior to this, Mr. Hosein served from June 2008 to October 2012 as Chief Financial Officer of Marvell Technology Group Ltd., a publicly traded semiconductor provider of high-performance analog, mixed-signal, digital signal processing and embedded microprocessor integrated circuits, and he also served as its Interim Chief Operating Officer and Secretary from October 2008 to March 2010. From 2003 to 2008 he served as Vice President and Chief Financial Officer of Integrated Device Technology, Inc., a provider of mixed-signal semiconductor solutions. From 2001 to 2003 he served as Senior Vice President, Finance and Administration and Chief Financial Officer of Advanced Interconnect Technologies, a semiconductor assembly and test company. He has also held other senior level financial positions, including the role of Chief Financial Officer at Candescent Technologies, a developer of flat panel display technology. Early in his career he spent 14 years in financial and engineering roles at IBM Corporation. Mr. Hosein has been a member of the Board of Directors of Wolfspeed, Inc. formerly Cree, Inc. since December 2005. - Clyde R. Hosein，2005年12月起，他是董事会成员；2013年8月起，他担任RingCentral（软件服务云为基础的商业通信解决方案供应商）行政副总裁兼首席财务官；2008年6月至2012年10月，他在Marvell Technology Group Ltd（高性能模拟，混合信号，数字信号处理和嵌入式微处理器集成电路的公开交易的半导体供应商）担任首席财务官；2008年10月至2010年3月，他还是Marvell Technology Group Ltd候补首席运营官兼秘书；2003年至2008年，他是Integrated Device Technology（重要混合信号半导体解决方案供应商）副总裁兼首席财务官；2001年至2003年，他是Advanced Interconnect Technologies（半导体封装和测试公司）财务部、行政部高级副总裁兼首席财务官。他还在Candescent Technologies（开发的平板显示技术开发商）担任过多个高级财务职位。在他的职业生涯早期，他在IBM Corporation的财务和工程方面工作14年。Hosein先生拥有纽约大学斯特恩商学院工商管理硕士学位和纽约理工大学工业工程学士学位。
- Clyde R. Hosein has served as Chief Financial Officer of AliveCor Inc., a medical device and AI company producing ECG hardware and software for consumer mobile devices, since March 2021. Prior to AliveCor, Mr. Hosein served as Chief Financial Officer of Automation Anywhere, Inc., an enterprise software provider of robotic process automation, from December 2017 to March 2021. From August 2013 to May 2017 he served as Executive Vice President and Chief Financial Officer of RingCentral, Inc., a publicly traded provider of software-as-a-service cloud-based business communications solutions. Prior to this, Mr. Hosein served from June 2008 to October 2012 as Chief Financial Officer of Marvell Technology Group Ltd., a publicly traded semiconductor provider of high-performance analog, mixed-signal, digital signal processing and embedded microprocessor integrated circuits, and he also served as its Interim Chief Operating Officer and Secretary from October 2008 to March 2010. From 2003 to 2008 he served as Vice President and Chief Financial Officer of Integrated Device Technology, Inc., a provider of mixed-signal semiconductor solutions. From 2001 to 2003 he served as Senior Vice President, Finance and Administration and Chief Financial Officer of Advanced Interconnect Technologies, a semiconductor assembly and test company. He has also held other senior level financial positions, including the role of Chief Financial Officer at Candescent Technologies, a developer of flat panel display technology. Early in his career he spent 14 years in financial and engineering roles at IBM Corporation. Mr. Hosein has been a member of the Board of Directors of Wolfspeed, Inc. formerly Cree, Inc. since December 2005.
- Leslie F. Varon
-
Leslie F. Varon，目前担任Xerox的临时首席财务官。她曾于2015年2月担任投资者关系副总裁，并于2001年8月被任命为公司的副总裁。她曾担任Xerox公司的多种高级职务。作为Xerox公司的临时首席财务官，她负责所有金融、财政、投资者关系、风险管理、合并和收购、税务和审计业务。作为投资者关系主管，她负责与股东和投资界沟通，并解释Xerox公司的财务业绩和业务策略。此前，她曾担任公司总会计师，负责推动公司的财政转换活动，包括全球财务共享服务中心、企业财务计划和分析、全球房地产和企业风险管理。她此前曾担任Xerox North America公司的财务和运营支持副总裁，并为公司在美国和加拿大的销售业务提供金融和战略领导。她于2004年10月担任该职位。1997年至2004年，她曾担任Xerox公司的投资者关系主管，并于2001年被任命为公司秘书。她于1980年加入Xerox公司，担任财务分析师，也曾担任负责Xerox公司的销售运营的多种运营财务和总会计师职务。她于1993年被任命为公司审计主管，并领导Xerox公司的全球审计组织的所有方面。她持有Binghamton University的学士学位，以及Virginia Tech的工商管理硕士学位（主修财务和营销）。
Leslie F. Varon,is the former Chief Financial Officer of Xerox Corporation, a document solutions company, a position she held from November 2015 until December 2016. From January 2017 until March 2017, when she retired from the company, she was a Special Advisor to the then new Xerox Chief Executive Officer. Her previous leadership roles during her tenure at Xerox include: Vice President, Investor Relations from March 2015 until October 2015; Vice President, Finance and Corporate Controller from July 2006 until February 2015, where she oversaw global financial operating executives and had responsibility for corporate financial planning and analysis, accounting, internal audit, risk management, global real estate and worldwide shared services centers; Vice President, North America Finance and Operational Support from October 2004 until June 2006; Vice President, Investor Relations and Corporate Secretary from 1997 until September 2004; and Director of Corporate Audit from 1993 until 1997.Ms. Varon has served as a member of the boards of directors of: Dentsply Sirona, Inc., a manufacturer and distributor of dental product solutions, since January 2018, where she chairs the audit and finance committee; and Hamilton Lane, a private markets investment company, since May 2017, where she is the chair of the audit committee. She previously served on the board of directors of Xerox International Partners, a joint venture of Xerox and Fuji Xerox, from July 2006 until March 2017.Ms. Varon earned an M.B.A. degree from Virginia Tech, and a B.S. degree in Psychology from Binghamton University. - Leslie F. Varon，目前担任Xerox的临时首席财务官。她曾于2015年2月担任投资者关系副总裁，并于2001年8月被任命为公司的副总裁。她曾担任Xerox公司的多种高级职务。作为Xerox公司的临时首席财务官，她负责所有金融、财政、投资者关系、风险管理、合并和收购、税务和审计业务。作为投资者关系主管，她负责与股东和投资界沟通，并解释Xerox公司的财务业绩和业务策略。此前，她曾担任公司总会计师，负责推动公司的财政转换活动，包括全球财务共享服务中心、企业财务计划和分析、全球房地产和企业风险管理。她此前曾担任Xerox North America公司的财务和运营支持副总裁，并为公司在美国和加拿大的销售业务提供金融和战略领导。她于2004年10月担任该职位。1997年至2004年，她曾担任Xerox公司的投资者关系主管，并于2001年被任命为公司秘书。她于1980年加入Xerox公司，担任财务分析师，也曾担任负责Xerox公司的销售运营的多种运营财务和总会计师职务。她于1993年被任命为公司审计主管，并领导Xerox公司的全球审计组织的所有方面。她持有Binghamton University的学士学位，以及Virginia Tech的工商管理硕士学位（主修财务和营销）。
- Leslie F. Varon,is the former Chief Financial Officer of Xerox Corporation, a document solutions company, a position she held from November 2015 until December 2016. From January 2017 until March 2017, when she retired from the company, she was a Special Advisor to the then new Xerox Chief Executive Officer. Her previous leadership roles during her tenure at Xerox include: Vice President, Investor Relations from March 2015 until October 2015; Vice President, Finance and Corporate Controller from July 2006 until February 2015, where she oversaw global financial operating executives and had responsibility for corporate financial planning and analysis, accounting, internal audit, risk management, global real estate and worldwide shared services centers; Vice President, North America Finance and Operational Support from October 2004 until June 2006; Vice President, Investor Relations and Corporate Secretary from 1997 until September 2004; and Director of Corporate Audit from 1993 until 1997.Ms. Varon has served as a member of the boards of directors of: Dentsply Sirona, Inc., a manufacturer and distributor of dental product solutions, since January 2018, where she chairs the audit and finance committee; and Hamilton Lane, a private markets investment company, since May 2017, where she is the chair of the audit committee. She previously served on the board of directors of Xerox International Partners, a joint venture of Xerox and Fuji Xerox, from July 2006 until March 2017.Ms. Varon earned an M.B.A. degree from Virginia Tech, and a B.S. degree in Psychology from Binghamton University.
- Willie A. Deese
-
Willie A. Deese， 自2008年起担任默克公司执行副总裁；自2005年起担任默克制造部总裁。2004年加入默克公司担任公司全球采购部高级副总裁；他曾担任葛兰素史克公司全球采购和物流高级副总裁以及永皇研究中心购买部副总裁。
Willie A. Deese,Director of PSE&G (wholly owned subsidiary of PSEG) since December 2023.EVP of Merck & Co. Inc., which develops, manufactures and distributes pharmaceuticals, from January 2008 until June 2016, President of Merck Manufacturing Division from 2005 until 2008, and SVP of Global Procurement at Merck from 2004 to 2005. Prior to that, SVP of Global Procurement and Logistics at GlaxoSmithKline, a pharmaceutical company.MBA, Western New England College; BA – Business Administration, North Carolina A&T State University. - Willie A. Deese， 自2008年起担任默克公司执行副总裁；自2005年起担任默克制造部总裁。2004年加入默克公司担任公司全球采购部高级副总裁；他曾担任葛兰素史克公司全球采购和物流高级副总裁以及永皇研究中心购买部副总裁。
- Willie A. Deese,Director of PSE&G (wholly owned subsidiary of PSEG) since December 2023.EVP of Merck & Co. Inc., which develops, manufactures and distributes pharmaceuticals, from January 2008 until June 2016, President of Merck Manufacturing Division from 2005 until 2008, and SVP of Global Procurement at Merck from 2004 to 2005. Prior to that, SVP of Global Procurement and Logistics at GlaxoSmithKline, a pharmaceutical company.MBA, Western New England College; BA – Business Administration, North Carolina A&T State University.
- Betsy D. Holden
-
Betsy D. Holden，2012年12月以来，她担任董事。2007年4月以来，她是McKinsey & Company（全球管理咨询公司）的高级顾问。从2004年1月到2005年5月，她担任Kraft Foods Inc.（ Altria Group, Inc.的食品单元）的全球营销和分类发展总裁。从2001年3月到2003年12月，她担任Kraft Foods Inc. 的首席执行官。从2000年5月到2003年12月，她担任Kraft Foods North America的总裁和首席执行官。1982年她的事业始于General Foods。她目前担任Western Union Company NYSE： WU和Diageo plc （NYSE： DEO）的董事。她在 Northwestern University's Kellogg School 的院长咨询委员会和Duke University's Trinity College的访客委员会任职。她获得Duke University的教育学士学位和Northwestern University的工商管理硕士学位。
Betsy D. Holden,has served as a Director of Kenvue since May 2023. Ms. Holden served as a Senior Advisor to McKinsey & Company from 2007 to 2020. She previously held several leadership roles at Kraft Foods, including Co-Chief Executive Officer of Kraft Foods Inc., President, Global Marketing and Category Development of Kraft Foods Inc. and President and Chief Executive Officer of Kraft Foods North America. Ms. Holden has served on nine public boards over the last 20 years, including Diageo Plc (2009 to 2018) and Time, Inc. (2014 to 2018). She currently serves as a board member for Dentsply Sirona Inc., National Retail Properties, Inc., Western Union Company and several private portfolio companies of Paine Schwartz Partners, a private equity firm focused on sustainable agriculture and food products for which she sits on the Food Chain Advisory Board. She also serves on the Executive Committee of Duke University's Board of Trustees and the Global Advisory Board of Northwestern University's Kellogg School of Management. Ms. Holden holds a B.A. degree in Education from Duke University as well as an M.A. degree in Teaching and an MBA degree, each from Northwestern University. - Betsy D. Holden，2012年12月以来，她担任董事。2007年4月以来，她是McKinsey & Company（全球管理咨询公司）的高级顾问。从2004年1月到2005年5月，她担任Kraft Foods Inc.（ Altria Group, Inc.的食品单元）的全球营销和分类发展总裁。从2001年3月到2003年12月，她担任Kraft Foods Inc. 的首席执行官。从2000年5月到2003年12月，她担任Kraft Foods North America的总裁和首席执行官。1982年她的事业始于General Foods。她目前担任Western Union Company NYSE： WU和Diageo plc （NYSE： DEO）的董事。她在 Northwestern University's Kellogg School 的院长咨询委员会和Duke University's Trinity College的访客委员会任职。她获得Duke University的教育学士学位和Northwestern University的工商管理硕士学位。
- Betsy D. Holden,has served as a Director of Kenvue since May 2023. Ms. Holden served as a Senior Advisor to McKinsey & Company from 2007 to 2020. She previously held several leadership roles at Kraft Foods, including Co-Chief Executive Officer of Kraft Foods Inc., President, Global Marketing and Category Development of Kraft Foods Inc. and President and Chief Executive Officer of Kraft Foods North America. Ms. Holden has served on nine public boards over the last 20 years, including Diageo Plc (2009 to 2018) and Time, Inc. (2014 to 2018). She currently serves as a board member for Dentsply Sirona Inc., National Retail Properties, Inc., Western Union Company and several private portfolio companies of Paine Schwartz Partners, a private equity firm focused on sustainable agriculture and food products for which she sits on the Food Chain Advisory Board. She also serves on the Executive Committee of Duke University's Board of Trustees and the Global Advisory Board of Northwestern University's Kellogg School of Management. Ms. Holden holds a B.A. degree in Education from Duke University as well as an M.A. degree in Teaching and an MBA degree, each from Northwestern University.
- Gregory T. Lucier
-
Gregory T. Lucier从2013年12月起担任董事会成员。他拥有超过20年的行政管理经验，在Life Technologies Corporation—一家管球生物技术公司担任董事会主席和CEO，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。之前，他从2003年5月开始担任 Invitrogen Corporation的CEO，直到Invitrogen Corporation 和 Applied Biosystems在2008年11月合并成为 Life Technologies。在加入Invitrogen Corporation之前，他在GE Medical Systems Information Technologies担任CEO和主席，在GE Medical Systems担任副主席分管全球服务，担任GE-Harris Railway Electronics的主席。他目前担任RainTree Oncology Services, CareFusion, Synthetic Genomics, Rady Children’s Hospital的董事会成员，是Sanford-Burnham Medical Research Institute。的董事会主席。他在Pennsylvania State University以优异的成绩获得工业工程理学学士学位，在Harvard Graduate School of Business Administration获得工商管理硕士学位。
Gregory T. Lucier,has been a member of the Board since April 2015. Mr. Lucier has served as the chief executive officer of Corza Health, Inc., a company focused on acquiring companies and assets as part of a strategy to build a market-leading healthcare business since 2019. Prior to that, he served as Chief Executive Officer of NuVasive, Inc., a medical device company, from 2015 to 2018. Before joining NuVasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation (formerly Invitrogen Corporation), a global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is chairman of the board of Berkeley Lights and serves as a director of Dentsply Sirona and Maravai LifeSciences. He previously served as a director of Life Technologies Corporation from May 2003 to February 2014, of Carefusion Corporation from August 2009 until its sale to Becton Dickinson in March 2015, of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018, and of Nuvasive from December 2013 to May 2021. Mr. Lucier received an M.B.A. from Harvard Business School and a B.S. in industrial engineering from Pennsylvania State University. - Gregory T. Lucier从2013年12月起担任董事会成员。他拥有超过20年的行政管理经验，在Life Technologies Corporation—一家管球生物技术公司担任董事会主席和CEO，直到该公司于2014年2月被Thermo Fisher Scientific Inc.收购。之前，他从2003年5月开始担任 Invitrogen Corporation的CEO，直到Invitrogen Corporation 和 Applied Biosystems在2008年11月合并成为 Life Technologies。在加入Invitrogen Corporation之前，他在GE Medical Systems Information Technologies担任CEO和主席，在GE Medical Systems担任副主席分管全球服务，担任GE-Harris Railway Electronics的主席。他目前担任RainTree Oncology Services, CareFusion, Synthetic Genomics, Rady Children’s Hospital的董事会成员，是Sanford-Burnham Medical Research Institute。的董事会主席。他在Pennsylvania State University以优异的成绩获得工业工程理学学士学位，在Harvard Graduate School of Business Administration获得工商管理硕士学位。
- Gregory T. Lucier,has been a member of the Board since April 2015. Mr. Lucier has served as the chief executive officer of Corza Health, Inc., a company focused on acquiring companies and assets as part of a strategy to build a market-leading healthcare business since 2019. Prior to that, he served as Chief Executive Officer of NuVasive, Inc., a medical device company, from 2015 to 2018. Before joining NuVasive, Mr. Lucier was Chairman and Chief Executive Officer of Life Technologies Corporation (formerly Invitrogen Corporation), a global biotechnology company, from May 2003 until it was acquired by Thermo Fisher Scientific Inc. in February 2014. Prior to that, Mr. Lucier was a corporate officer at General Electric Company, where he served in a variety of leadership roles. Mr. Lucier is chairman of the board of Berkeley Lights and serves as a director of Dentsply Sirona and Maravai LifeSciences. He previously served as a director of Life Technologies Corporation from May 2003 to February 2014, of Carefusion Corporation from August 2009 until its sale to Becton Dickinson in March 2015, of Invuity, Inc. from October 2014 until its sale to Stryker in October 2018, and of Nuvasive from December 2013 to May 2021. Mr. Lucier received an M.B.A. from Harvard Business School and a B.S. in industrial engineering from Pennsylvania State University.
高管简历
中英对照 | 中文 | 英文- Simon D. Campion
Simon D. Campion自2022年9月12日起担任Dentsply Sirona Inc.总裁兼首席执行官，并担任Dentsply Sirona Inc.董事会成员。在加入Dentsply Sirona之前，Campion先生曾担任Becton，Dickinson and Company（“BD”）的执行副总裁兼医疗部门总裁，该职位于2022年7月开始担任。在此之前，Campion先生自2018年9月起担任BD干预部门的执行副总裁兼总裁，在此之前，他是BD手术业务部门的总裁，在那里他将传统的C.R.Bard，Inc.（“Bard”）和BD产品平台集成到一个集成手术产品中。Campion先生于2008年加入Bard，在美国和国际上的许多Bard公司担任领导职务。在加入Bard之前，他曾在Cook Medical和Boston Scientific担任营销和研发职务。Campion先生拥有University of Limerick in Ireland机械工程博士学位和The Open University in the United Kingdom工商管理硕士学位。
Simon D. Campion,has served as Dentsply Sirona Inc. President and Chief Executive Officer and as a member of the Company's Board of Directors since September 12, 2022. Prior to joining Dentsply Sirona, Mr. Campion served as the Executive Vice President and President of the Medical Segment of Becton, Dickinson and Company ("BD"), a position held beginning in July 2022. Prior to that, Mr. Campion served as the Executive Vice President and President of the Interventional segment for BD since September 2018 and, prior to that, he was president of the BD Surgery business unit, where he integrated legacy C. R. Bard, Inc. ("Bard") and BD product platforms into an integrated surgery offering. Mr. Campion joined Bard in 2008 and held leadership roles in numerous Bard businesses in the U.S. and Internationally. Prior to Bard, he held marketing and R&D roles at Cook Medical and Boston Scientific. Mr. Campion holds a Ph.D. in Mechanical Engineering from the University of Limerick in Ireland and a Master of Business Administration from The Open University in the United Kingdom.- Simon D. Campion自2022年9月12日起担任Dentsply Sirona Inc.总裁兼首席执行官，并担任Dentsply Sirona Inc.董事会成员。在加入Dentsply Sirona之前，Campion先生曾担任Becton，Dickinson and Company（“BD”）的执行副总裁兼医疗部门总裁，该职位于2022年7月开始担任。在此之前，Campion先生自2018年9月起担任BD干预部门的执行副总裁兼总裁，在此之前，他是BD手术业务部门的总裁，在那里他将传统的C.R.Bard，Inc.（“Bard”）和BD产品平台集成到一个集成手术产品中。Campion先生于2008年加入Bard，在美国和国际上的许多Bard公司担任领导职务。在加入Bard之前，他曾在Cook Medical和Boston Scientific担任营销和研发职务。Campion先生拥有University of Limerick in Ireland机械工程博士学位和The Open University in the United Kingdom工商管理硕士学位。
- Simon D. Campion,has served as Dentsply Sirona Inc. President and Chief Executive Officer and as a member of the Company's Board of Directors since September 12, 2022. Prior to joining Dentsply Sirona, Mr. Campion served as the Executive Vice President and President of the Medical Segment of Becton, Dickinson and Company ("BD"), a position held beginning in July 2022. Prior to that, Mr. Campion served as the Executive Vice President and President of the Interventional segment for BD since September 2018 and, prior to that, he was president of the BD Surgery business unit, where he integrated legacy C. R. Bard, Inc. ("Bard") and BD product platforms into an integrated surgery offering. Mr. Campion joined Bard in 2008 and held leadership roles in numerous Bard businesses in the U.S. and Internationally. Prior to Bard, he held marketing and R&D roles at Cook Medical and Boston Scientific. Mr. Campion holds a Ph.D. in Mechanical Engineering from the University of Limerick in Ireland and a Master of Business Administration from The Open University in the United Kingdom.
- Lisa M. Yankie
Lisa M. Yankie自2019年10月起担任DENTSPLY SIRONA Inc.高级副总裁、首席人力资源官和传讯官。加入dentspy Sirona之前，Yankie女士于2016年9月至2019年10月担任Domtar Corporation（全球造纸产品生产商）的企业和纸浆和造纸部门的人力资源副总裁。在此之前，她从2010年到2016年8月担任多行业制造和工程组织SPX Corporation的人力资源业务负责人。在此之前，她曾在Dana Incorporated、Bank of America和the Ford Motor Company担任多个行政职务。她持有密歇根州立大学（Michigan State University）工商管理学士学位和劳动关系和人力资源硕士学位。
Lisa M. Yankie has served as Senior Vice President, Chief Human Resources Officer and Communications of the Company since October 2019. Prior to joining Dentsply Sirona, Ms. Yankie served as Vice President of Human Resources for the Corporate & Pulp & Paper division of Domtar Corporation, a global producer of paper products, from September 2016 to October 2019. Before that, she was the HR business leader for the multi-industry manufacturing and engineering organization SPX Corporation from 2010 to August 2016. Prior to that, she served in various executive roles at Dana Incorporated, Bank of America and the Ford Motor Company. Ms. Yankie holds a bachelor’s degree in Business Administration and a master’s degree in Labor Relations and Human Resources both from Michigan State University.- Lisa M. Yankie自2019年10月起担任DENTSPLY SIRONA Inc.高级副总裁、首席人力资源官和传讯官。加入dentspy Sirona之前，Yankie女士于2016年9月至2019年10月担任Domtar Corporation（全球造纸产品生产商）的企业和纸浆和造纸部门的人力资源副总裁。在此之前，她从2010年到2016年8月担任多行业制造和工程组织SPX Corporation的人力资源业务负责人。在此之前，她曾在Dana Incorporated、Bank of America和the Ford Motor Company担任多个行政职务。她持有密歇根州立大学（Michigan State University）工商管理学士学位和劳动关系和人力资源硕士学位。
- Lisa M. Yankie has served as Senior Vice President, Chief Human Resources Officer and Communications of the Company since October 2019. Prior to joining Dentsply Sirona, Ms. Yankie served as Vice President of Human Resources for the Corporate & Pulp & Paper division of Domtar Corporation, a global producer of paper products, from September 2016 to October 2019. Before that, she was the HR business leader for the multi-industry manufacturing and engineering organization SPX Corporation from 2010 to August 2016. Prior to that, she served in various executive roles at Dana Incorporated, Bank of America and the Ford Motor Company. Ms. Yankie holds a bachelor’s degree in Business Administration and a master’s degree in Labor Relations and Human Resources both from Michigan State University.
- Erania Brackett
Erania Brackett 于 2021 年 8 月 2 日加入DENTSPLY SIRONA，目前担任DENTSPLY SIRONA高级副总裁、首席营销官。 在加入登士柏西诺德之前，Brackett 女士自 2017 年 12 月起在医疗技术公司美敦力 （Medtronic） 担任 CRHF 患者管理全球商业营销副总裁。在加入美敦力之前，她曾在通用电气医疗技术子公司 GE Healthcare 工作 Electric，工作了 15 年，担任过各种商业和运营领导职务。 在加入 GE Healthcare 之前，Brackett 女士曾在消费品公司宝洁公司工作，并担任过多个工程、运营管理和持续改进职位。 Brackett 女士拥有塔斯基吉大学的化学工程学士学位。
Erania Brackett joined the company on August 2 2021 and she currently serves as the Company's Senior Vice President, Chief Marketing Officer. Before joining Dentsply Sirona, Ms. Brackett served with Medtronic, a medical technology company, as its Vice President, Global Commercial Marketing, Patient Management, CRHF since December 2017. Before joining Medtronic, she worked at GE Healthcare, a medical technology subsidiary of General Electric, for 15 years and held various commercial and operational leadership roles. Before joining GE Healthcare, Ms. Brackett worked for Procter and Gamble, a consumer goods company, and held several engineering, operations management, and continuous improvement positions. Ms. Brackett holds a bachelor's degree in chemical engineering from the Tuskegee University.- Erania Brackett 于 2021 年 8 月 2 日加入DENTSPLY SIRONA，目前担任DENTSPLY SIRONA高级副总裁、首席营销官。 在加入登士柏西诺德之前，Brackett 女士自 2017 年 12 月起在医疗技术公司美敦力 （Medtronic） 担任 CRHF 患者管理全球商业营销副总裁。在加入美敦力之前，她曾在通用电气医疗技术子公司 GE Healthcare 工作 Electric，工作了 15 年，担任过各种商业和运营领导职务。 在加入 GE Healthcare 之前，Brackett 女士曾在消费品公司宝洁公司工作，并担任过多个工程、运营管理和持续改进职位。 Brackett 女士拥有塔斯基吉大学的化学工程学士学位。
- Erania Brackett joined the company on August 2 2021 and she currently serves as the Company's Senior Vice President, Chief Marketing Officer. Before joining Dentsply Sirona, Ms. Brackett served with Medtronic, a medical technology company, as its Vice President, Global Commercial Marketing, Patient Management, CRHF since December 2017. Before joining Medtronic, she worked at GE Healthcare, a medical technology subsidiary of General Electric, for 15 years and held various commercial and operational leadership roles. Before joining GE Healthcare, Ms. Brackett worked for Procter and Gamble, a consumer goods company, and held several engineering, operations management, and continuous improvement positions. Ms. Brackett holds a bachelor's degree in chemical engineering from the Tuskegee University.
- Andreas G. Frank
Andreas G. Frank，他于2022年4月加入公司。加入Dentsply Sirona之前，Frank先生曾担任Baxter International Inc前线护理总裁（2021年12月以来）。加入Baxter之前，他在Hill-Rom Holdings Inc.担任同一职位。此前在Hill-Rom担任的职务包括首席转型官和企业发展与战略高级副总裁。加入Hill-Rom之前，Frank先生曾担任Danaher Corporation的企业发展总监和业务发展副总裁。他曾在麦肯锡公司（McKinsey & Company）的公司财务和战略实践部门工作。Frank先生分别在德国Otto Beisheim管理学院和德克萨斯大学奥斯汀分校Red McCombs商学院获得工商管理和经济学硕士学位，并在德克萨斯大学获得工商管理硕士学位。
Andreas G. Frank,joined the Company in April 2022. Prior to joining Dentsply Sirona, Mr. Frank served as President, Front Line Care at Baxter International Inc since December 2021. Prior to Baxter he held the same position at Hill-Rom Holdings Inc. Prior roles at Hill-Rom included Chief Transformation Officer and Senior Vice President, Corporate Development and Strategy. Prior to joining Hill-Rom, Mr. Frank served as Director of Corporate Development and Vice President, Business Development, at Danaher Corporation. He previously worked in the Corporate Finance and Strategy practice at McKinsey & Company. Mr. Frank received his master's degrees in business administration and economics from the Otto Beisheim School of Management in Germany and the University of Texas at Austin, Red McCombs School of Business, respectively, and an MBA from The University of Texas.- Andreas G. Frank，他于2022年4月加入公司。加入Dentsply Sirona之前，Frank先生曾担任Baxter International Inc前线护理总裁（2021年12月以来）。加入Baxter之前，他在Hill-Rom Holdings Inc.担任同一职位。此前在Hill-Rom担任的职务包括首席转型官和企业发展与战略高级副总裁。加入Hill-Rom之前，Frank先生曾担任Danaher Corporation的企业发展总监和业务发展副总裁。他曾在麦肯锡公司（McKinsey & Company）的公司财务和战略实践部门工作。Frank先生分别在德国Otto Beisheim管理学院和德克萨斯大学奥斯汀分校Red McCombs商学院获得工商管理和经济学硕士学位，并在德克萨斯大学获得工商管理硕士学位。
- Andreas G. Frank,joined the Company in April 2022. Prior to joining Dentsply Sirona, Mr. Frank served as President, Front Line Care at Baxter International Inc since December 2021. Prior to Baxter he held the same position at Hill-Rom Holdings Inc. Prior roles at Hill-Rom included Chief Transformation Officer and Senior Vice President, Corporate Development and Strategy. Prior to joining Hill-Rom, Mr. Frank served as Director of Corporate Development and Vice President, Business Development, at Danaher Corporation. He previously worked in the Corporate Finance and Strategy practice at McKinsey & Company. Mr. Frank received his master's degrees in business administration and economics from the Otto Beisheim School of Management in Germany and the University of Texas at Austin, Red McCombs School of Business, respectively, and an MBA from The University of Texas.
- Robert A. Johnson
Robert A. Johnson，于2022年11月加入Dentsply Sirona，目前担任首席供应链官。加入公司之前，Johnson先生是Cardinal Health的全球产品和供应链总裁。在此之前，他曾担任Becton Dickinson / CR Bard的高级副总裁，负责他们的介入部门，并在Baxter International工作了25年，在那里他在美国和国际上担任领导业务的职位。他在阿肯色大学（University of Arkansas）获得工业工程学士学位。
Robert A. Johnson,joined Dentsply Sirona in November 2022 and currently serves as Chief Supply Chain Officer. Prior to joining the Company, Mr. Johnson was President of Global Products and Supply Chain at Cardinal Health. Prior to that, he was Senior Vice President of Operations at Becton Dickinson / CR Bard where he was responsible for their Interventional Segment and spent 25 years with Baxter International where he held positions leading operations both in the United States and internationally. Mr. Johnson received his bachelor's degree in industrial engineering from the University of Arkansas.- Robert A. Johnson，于2022年11月加入Dentsply Sirona，目前担任首席供应链官。加入公司之前，Johnson先生是Cardinal Health的全球产品和供应链总裁。在此之前，他曾担任Becton Dickinson / CR Bard的高级副总裁，负责他们的介入部门，并在Baxter International工作了25年，在那里他在美国和国际上担任领导业务的职位。他在阿肯色大学（University of Arkansas）获得工业工程学士学位。
- Robert A. Johnson,joined Dentsply Sirona in November 2022 and currently serves as Chief Supply Chain Officer. Prior to joining the Company, Mr. Johnson was President of Global Products and Supply Chain at Cardinal Health. Prior to that, he was Senior Vice President of Operations at Becton Dickinson / CR Bard where he was responsible for their Interventional Segment and spent 25 years with Baxter International where he held positions leading operations both in the United States and internationally. Mr. Johnson received his bachelor's degree in industrial engineering from the University of Arkansas.
- Richard C. Rosenzweig
Richard C. Rosenzweig，他于2023年2月加入dentspply Sirona，目前担任企业发展高级副总裁、总法律顾问和秘书。加入公司之前，Rosenzweig先生曾担任AngioDynamics的高级副总裁、总法律顾问和秘书，在那里他领导法律部门，包括合规，并担任这家上市医疗设备公司的董事会秘书。此前，他在C. R. Bard Inc.任职十多年，担任过多个职位，包括副总裁、法律和助理秘书，以及公司管理委员会成员。其他经验包括在其他上市公司担任法律总顾问，以及在强生公司担任领导职务。他是Rutgers生物医学和健康科学的董事领导委员会成员，并曾担任新泽西州Rutgers癌症研究所董事领导顾问15年。Rosenzweig先生在波士顿大学法学院获得法律学位，并在Brandeis大学获得心理学学士学位。
Richard C. Rosenzweig,joined Dentsply Sirona in February 2023 and currently serves as Senior Vice President, Corporate Development, General Counsel and Secretary. Prior to joining the Company, Mr. Rosenzweig served as Senior Vice President, General Counsel & Secretary at AngioDynamics where he led the legal department including compliance and served as Secretary to the Board for this publicly traded medical device company. Previously, he held several roles during his more than ten years at C. R. Bard Inc., including serving as Vice President, Law & Assistant Secretary, and being a Member of the Corporate Management Committee. Other previous experiences include General Counsel roles at other public companies and a leading role at Johnson & Johnson. He is a member of the Director's Leadership Council at Rutgers Biomedical and Health Sciences and has served as a member of the Rutgers Cancer Institute of New Jersey Director's Leadership Counsel for 15 years. Mr. Rosenzweig earned his law degree from Boston University School of Law and holds a Bachelor of Arts, Psychology, from Brandeis University.- Richard C. Rosenzweig，他于2023年2月加入dentspply Sirona，目前担任企业发展高级副总裁、总法律顾问和秘书。加入公司之前，Rosenzweig先生曾担任AngioDynamics的高级副总裁、总法律顾问和秘书，在那里他领导法律部门，包括合规，并担任这家上市医疗设备公司的董事会秘书。此前，他在C. R. Bard Inc.任职十多年，担任过多个职位，包括副总裁、法律和助理秘书，以及公司管理委员会成员。其他经验包括在其他上市公司担任法律总顾问，以及在强生公司担任领导职务。他是Rutgers生物医学和健康科学的董事领导委员会成员，并曾担任新泽西州Rutgers癌症研究所董事领导顾问15年。Rosenzweig先生在波士顿大学法学院获得法律学位，并在Brandeis大学获得心理学学士学位。
- Richard C. Rosenzweig,joined Dentsply Sirona in February 2023 and currently serves as Senior Vice President, Corporate Development, General Counsel and Secretary. Prior to joining the Company, Mr. Rosenzweig served as Senior Vice President, General Counsel & Secretary at AngioDynamics where he led the legal department including compliance and served as Secretary to the Board for this publicly traded medical device company. Previously, he held several roles during his more than ten years at C. R. Bard Inc., including serving as Vice President, Law & Assistant Secretary, and being a Member of the Corporate Management Committee. Other previous experiences include General Counsel roles at other public companies and a leading role at Johnson & Johnson. He is a member of the Director's Leadership Council at Rutgers Biomedical and Health Sciences and has served as a member of the Rutgers Cancer Institute of New Jersey Director's Leadership Counsel for 15 years. Mr. Rosenzweig earned his law degree from Boston University School of Law and holds a Bachelor of Arts, Psychology, from Brandeis University.
- Richard M. Wagner
Richard M. Wagner，他一直担任公司的首席会计官（2022年8月以来）。他此前曾担任Hillrom的副总裁、首席会计官和公司总会计师，监督财务收尾流程、报告、控制合规流程和共享服务组织。他积极参与了多项收购的整合，领导了财务组织的运营改进，并与运营领导层合作实施全球流程。在2018年加入Hillrom之前，他曾担任CREE, Inc.的照明副总裁兼财务总监，领导照明部门，并领导对大型收购的财务分析流程和尽职调查的重新设计。在CREE任职之前，他曾担任dentspply Sirona的副总裁、公司财务总监，直到2017年，他在dentspply和Sirona合并的财务整合中发挥了重要作用。Wagner先生毕业于宾夕法尼亚州立大学会计学学士学位，是注册会计师。
Richard M. Wagner,has served as Chief Accounting Officer of the Company since August 2022. He previously served as the Vice President, Chief Accounting Officer and Corporate Controller at Hillrom overseeing the financial close process, reporting, control compliance processes and the shared services organization. He was heavily involved in integrating multiple acquisitions, leading operational improvements in the finance organization and partnering with operating leadership to implement global processes. Before joining Hillrom in 2018, he served as the Vice President and Controller, Lighting at CREE, Inc. he provided leadership for the lighting division and led the re-design of the financial analysis process and due diligence for large acquisitions. Prior to his tenure at CREE, he was the Vice President, Corporate Controller at Dentsply Sirona until 2017 where he was instrumental in the financial integration of the merger between Dentsply and Sirona. Mr. Wagner graduated with a B.S. in Accounting from Penn State University and is a CPA.- Richard M. Wagner，他一直担任公司的首席会计官（2022年8月以来）。他此前曾担任Hillrom的副总裁、首席会计官和公司总会计师，监督财务收尾流程、报告、控制合规流程和共享服务组织。他积极参与了多项收购的整合，领导了财务组织的运营改进，并与运营领导层合作实施全球流程。在2018年加入Hillrom之前，他曾担任CREE, Inc.的照明副总裁兼财务总监，领导照明部门，并领导对大型收购的财务分析流程和尽职调查的重新设计。在CREE任职之前，他曾担任dentspply Sirona的副总裁、公司财务总监，直到2017年，他在dentspply和Sirona合并的财务整合中发挥了重要作用。Wagner先生毕业于宾夕法尼亚州立大学会计学学士学位，是注册会计师。
- Richard M. Wagner,has served as Chief Accounting Officer of the Company since August 2022. He previously served as the Vice President, Chief Accounting Officer and Corporate Controller at Hillrom overseeing the financial close process, reporting, control compliance processes and the shared services organization. He was heavily involved in integrating multiple acquisitions, leading operational improvements in the finance organization and partnering with operating leadership to implement global processes. Before joining Hillrom in 2018, he served as the Vice President and Controller, Lighting at CREE, Inc. he provided leadership for the lighting division and led the re-design of the financial analysis process and due diligence for large acquisitions. Prior to his tenure at CREE, he was the Vice President, Corporate Controller at Dentsply Sirona until 2017 where he was instrumental in the financial integration of the merger between Dentsply and Sirona. Mr. Wagner graduated with a B.S. in Accounting from Penn State University and is a CPA.
- Glenn G. Coleman
Glenn G. Coleman是Integra的执行副总裁兼首席运营官。他负责监督Integra的运营和大部分的人才队伍，包括临床、研发、制造和质量，同时也领导Integra Lifesciences Holdings Corporation的国际团队。在2019年6月晋升为首席运营官之前，他担任公司的首席财务官，负责财务部门，包括会计和财务报告、预算、内部审计、税务、财务、投资者关系和信息技术，同时还领导Integra Lifesciences Holdings Corporation的国际业务。在2014年5月加入公司担任公司副总裁兼首席财务官之前，他在全球领先的企业担任了25年的财务管理职位，包括担任curtis - wright Corporation的财务副总裁和公司财务总监。他还曾在Alcatel-Lucent担任多个财务行政领导职位。他的职业生涯始于PricewaterhouseCoopers LLP.他持有Montclair State University的学士学位，也是新泽西州注册会计师超过25年。
Glenn G. Coleman is Integra's Executive Vice President and Chief Operating Officer. Mr. Coleman oversees Integra operations and a majority of Integra's talent force, including clinical, R&D, manufacturing and quality while also leading Integra Lifesciences Holdings Corporation international team. Prior to his promotion in June 2019 to Chief Operating Officer, he acted as the Company's Chief Financial Officer and was responsible for the finance department, including accounting and financial reporting, budgeting, internal audit, tax, treasury, investor relations, and information technology while also leading Integra Lifesciences Holdings Corporation international business. Prior to joining the Company in May 2014 as Corporate Vice President and Chief Financial Officer, he spent 25 years in financial management positions with leading global businesses, including serving as vice president for finance and corporate controller at Curtiss-Wright Corporation. He also worked at Alcatel-Lucent in various finance executive leadership positions. Mr. Coleman began his career at PricewaterhouseCoopers LLP. Mr. Coleman received his B.S. degree from Montclair State University and has also been a CPA in New Jersey for more than 25 years.- Glenn G. Coleman是Integra的执行副总裁兼首席运营官。他负责监督Integra的运营和大部分的人才队伍，包括临床、研发、制造和质量，同时也领导Integra Lifesciences Holdings Corporation的国际团队。在2019年6月晋升为首席运营官之前，他担任公司的首席财务官，负责财务部门，包括会计和财务报告、预算、内部审计、税务、财务、投资者关系和信息技术，同时还领导Integra Lifesciences Holdings Corporation的国际业务。在2014年5月加入公司担任公司副总裁兼首席财务官之前，他在全球领先的企业担任了25年的财务管理职位，包括担任curtis - wright Corporation的财务副总裁和公司财务总监。他还曾在Alcatel-Lucent担任多个财务行政领导职位。他的职业生涯始于PricewaterhouseCoopers LLP.他持有Montclair State University的学士学位，也是新泽西州注册会计师超过25年。
- Glenn G. Coleman is Integra's Executive Vice President and Chief Operating Officer. Mr. Coleman oversees Integra operations and a majority of Integra's talent force, including clinical, R&D, manufacturing and quality while also leading Integra Lifesciences Holdings Corporation international team. Prior to his promotion in June 2019 to Chief Operating Officer, he acted as the Company's Chief Financial Officer and was responsible for the finance department, including accounting and financial reporting, budgeting, internal audit, tax, treasury, investor relations, and information technology while also leading Integra Lifesciences Holdings Corporation international business. Prior to joining the Company in May 2014 as Corporate Vice President and Chief Financial Officer, he spent 25 years in financial management positions with leading global businesses, including serving as vice president for finance and corporate controller at Curtiss-Wright Corporation. He also worked at Alcatel-Lucent in various finance executive leadership positions. Mr. Coleman began his career at PricewaterhouseCoopers LLP. Mr. Coleman received his B.S. degree from Montclair State University and has also been a CPA in New Jersey for more than 25 years.